Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues). In 2024, 71% of the company's revenues came from the United States.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | 2026-02-18 03:59:39 | 60.4 | 0.05 | 0.08 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | 0000014272 | BRISTOL MYERS SQUIBB CO | US1101221083 | HLYYNH7UQUORYSJQCN42 | 220790350 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | DE | ROUTE 206 AND PROVINCE LINE ROAD | PRINCETON | NJ | 08543 | UNITED STATES | US | 6092524621 | ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543 | ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543 | — | Pharmaceuticals | 1887 | Chris Boerner | 34,100 | http://bms.com | 94,188,864,457 | 2,900,000,000 | 2,036,473,705 | Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues). In 2024, 71% of the company's revenues came from the United States. | 2026-02-12 15:12:33 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 94,188,864,457 | 10,032,440,544 | 11.9212 | 2,036,473,705 | 7,161,682 | 0.3529 |
| 2024 | 84,156,423,913 | -49,342,465,607 | -36.961 | 2,029,312,023 | 7,118,612 | 0.352 |
| 2023 | 133,498,889,520 | -30,802,163,319 | -18.7474 | 2,022,193,411 | -76,582,567 | -3.6489 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Samit Hirawat | Chief Medical Officer, EVP | 2024 | 1,115,000 | 0 | 5,617,762 | 1,564,234 | 289,018 | 8,586,014 |
| Sandra Leungevp And | General Counsel | 2024 | 1,150,000 | 0 | 3,959,204 | 1,613,335 | 289,251 | 7,011,790 |
| Christopher S. Boerner | Chair, Chief Executive Officer | 2024 | 1,536,538 | 0 | 13,643,063 | 3,235,581 | 372,436 | 18,787,618 |
| David V. Elkinsevp And | Chief Financial Officer | 2024 | 1,115,000 | 0 | 5,778,244 | 1,564,234 | 250,093 | 8,707,571 |
| Samit Hirawat | Chief Medical Officer, EVP | 2023 | 1,103,781 | 0 | 3,616,394 | 1,234,117 | 279,335 | 6,233,627 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 32,500 |
| 2024 | 34,100 |
| 2023 | 34,100 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 48,194,000,000 | 48,300,000,000 | 45,006,000,000 |
| Cost Of Revenue | 13,936,000,000 | 13,968,000,000 | 10,693,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 9,951,000,000 | 11,159,000,000 | 9,299,000,000 |
| General And Administrative Expenses | 7,267,000,000 | 8,414,000,000 | 7,772,000,000 |
| Operating Expenses | 38,866,000,000 | 56,679,000,000 | 36,566,000,000 |
| Operating Income | — | — | — |
| Net Income | 7,054,000,000 | -8,948,000,000 | 8,025,000,000 |
| Earnings Per Share Basic | 3.47 | -4.41 | 3.88 |
| Earnings Per Share Diluted | 3.46 | -4.41 | 3.86 |
| Weighted Average Shares Outstanding Basic | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 |
| Weighted Average Shares Outstanding Diluted | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 10,209,000,000 | 10,346,000,000 | 11,464,000,000 |
| Marketable Securities Current | 464,000,000 | 513,000,000 | 816,000,000 |
| Accounts Receivable | 11,414,000,000 | 10,747,000,000 | 10,921,000,000 |
| Inventories | 2,690,000,000 | 2,557,000,000 | 2,662,000,000 |
| Non Trade Receivables | 1,821,000,000 | 1,735,000,000 | 2,039,000,000 |
| Other Assets Current | 4,613,000,000 | 5,617,000,000 | 5,907,000,000 |
| Total Assets Current | 29,390,000,000 | 29,780,000,000 | 31,770,000,000 |
| Marketable Securities Non Current | 396,000,000 | 320,000,000 | 364,000,000 |
| Property Plant And Equipment | 7,543,000,000 | 7,136,000,000 | 6,646,000,000 |
| Other Assets Non Current | 6,474,000,000 | 6,105,000,000 | 5,370,000,000 |
| Total Assets Non Current | 60,648,000,000 | 62,823,000,000 | 63,389,000,000 |
| Total Assets | 90,038,000,000 | 92,603,000,000 | 95,159,000,000 |
| Accounts Payable | 3,575,000,000 | 3,602,000,000 | 3,259,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 2,261,000,000 | 2,046,000,000 | 3,119,000,000 |
| Other Liabilities Current | 17,581,000,000 | 18,126,000,000 | 15,884,000,000 |
| Total Liabilities Current | 23,417,000,000 | 23,774,000,000 | 22,262,000,000 |
| Long Term Debt | 44,827,000,000 | 49,431,000,000 | 39,526,000,000 |
| Other Liabilities Non Current | 5,043,000,000 | 4,469,000,000 | 6,421,000,000 |
| Total Liabilities Non Current | 48,116,000,000 | 52,441,000,000 | 43,412,000,000 |
| Total Liabilities | 71,533,000,000 | 76,215,000,000 | 65,674,000,000 |
| Common Stock | 292,000,000 | 292,000,000 | 292,000,000 |
| Retained Earnings | 16,896,000,000 | 14,912,000,000 | 28,766,000,000 |
| Accumulated Other Comprehensive Income | -1,524,000,000 | -1,238,000,000 | -1,546,000,000 |
| Total Shareholders Equity | 18,473,000,000 | 16,335,000,000 | 29,430,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 4,011,000,000 | 9,600,000,000 | 9,760,000,000 |
| Share Based Compensation Expense | 553,000,000 | 507,000,000 | 518,000,000 |
| Other Non Cash Income Expense | -232,000,000 | -94,000,000 | -308,000,000 |
| Change In Accounts Receivable | 295,000,000 | -264,000,000 | 995,000,000 |
| Change In Inventories | 184,000,000 | 486,000,000 | 751,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -2,000,000 | 184,000,000 | 198,000,000 |
| Change In Other Liabilities | -471,000,000 | -624,000,000 | 667,000,000 |
| Cash From Operating Activities | 14,156,000,000 | 15,190,000,000 | 13,860,000,000 |
| Purchases Of Marketable Securities | 2,000,000,000 | 769,000,000 | 1,774,000,000 |
| Sales Of Marketable Securities | 1,975,000,000 | 1,122,000,000 | 733,000,000 |
| Acquisition Of Property Plant And Equipment | 1,311,000,000 | 1,248,000,000 | 1,209,000,000 |
| Acquisition Of Business | 3,944,000,000 | 21,821,000,000 | 1,169,000,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -4,132,000,000 | -21,352,000,000 | -2,295,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 5,045,000,000 | 4,863,000,000 | 4,744,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 0 | 0 | 5,155,000,000 |
| Issuance Of Long Term Debt | 5,740,000,000 | 12,883,000,000 | 4,455,000,000 |
| Repayment Of Long Term Debt | 10,940,000,000 | 2,873,000,000 | 3,879,000,000 |
| Other Financing Activities | — | — | 27,000,000 |
| Cash From Financing Activities | -10,348,000,000 | 5,127,000,000 | -9,416,000,000 |
| Change In Cash | -129,000,000 | -1,172,000,000 | 2,194,000,000 |
| Cash At End Of Period | 10,209,000,000 | 10,346,000,000 | 11,464,000,000 |
| Income Taxes Paid | 3,264,000,000 | 3,900,000,000 | 4,300,000,000 |
| Interest Paid | 2,100,000,000 | 1,800,000,000 | 1,200,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 3.47 | -4.41 | 3.88 |
| Price To Earnings Ratio | 15.5447 | -12.8254 | 13.2242 |
| Earnings Growth Rate | -178.6848 | -213.6598 | 30.6397 |
| Price Earnings To Growth Ratio | -0.087 | 0.06 | 0.4316 |
| Book Value Per Share | 9.0978 | 8.0849 | 14.2508 |
| Price To Book Ratio | 5.9289 | 6.9958 | 3.6005 |
| Ebitda | 16,220,000,000 | 6,499,000,000 | 23,251,000,000 |
| Enterprise Value | 146,592,960,000 | 155,778,120,000 | 137,341,390,000 |
| Dividend Yield | 0.046 | 0.0424 | 0.0447 |
| Dividend Payout Ratio | 0.7152 | -0.5435 | 0.5912 |
| Debt To Equity Ratio | 2.549 | 3.1513 | 1.449 |
| Capital Expenditures | 4,418,000,000 | 10,090,000,000 | 10,151,000,000 |
| Free Cash Flow | 9,738,000,000 | 5,100,000,000 | 3,709,000,000 |
| Return On Equity | 0.3819 | -0.5478 | 0.2727 |
| One Year Beta | 0.3129 | 0.1352 | 0.439 |
| Three Year Beta | 0.2997 | 0.2814 | 0.3207 |
| Five Year Beta | 0.2972 | 0.4631 | 0.52 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Arduini Peter J | Director | 2026-02-01 | 3,996 | A | 70,858 |
| Bhatt Deepak | Director | 2026-02-01 | 3,996 | A | 19,241 |
| Haller Julia A | Director | 2026-02-01 | 3,996 | A | 37,903 |
| Hickey Benjamin | President, RayzeBio Org. | 2026-02-01 | 10,079 | A | 18,868 |
| Hickey Benjamin | President, RayzeBio Org. | 2026-02-01 | 3,810 | D | 15,058 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H Tuberville | Senator | 2025-05-15 | Sale (Full) | 2025-04-15 | Self | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-05-15 | Purchase | 2024-04-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-05-15 | Sale (Full) | 2024-04-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-02-14 | Sale (Partial) | 2024-01-03 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2023-12-15 | Sale (Full) | 2023-11-16 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julie Johnson | 2026-01-15 | TX32 | Sale | 2025-12-18 | Joint | $1,001 - $15,000 |
| Julia Letlow | 2026-01-13 | LA05 | Sale | 2025-04-28 | — | $1,001 - $15,000 |
| Julia Letlow | 2026-01-13 | LA05 | Purchase | 2024-10-23 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2026-01-12 | CA31 | Purchase | 2025-12-19 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-12-15 | CA31 | Purchase | 2025-11-12 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GAM Holding AG | 2025-12-31 | 4,687,170 | 86,896 | 53.94 |
| Abel Hall, LLC | 2025-12-31 | 1,098,488 | 20,365 | 53.94 |
| WFA of San Diego, LLC | 2025-12-31 | 57,338 | 1,063 | 53.9398 |
| LAZARD ASSET MANAGEMENT LLC | 2025-12-31 | 83,922,172 | 1,555,843 | 53.94 |
| Cetera Investment Advisers | 2025-12-31 | 2 | 100 | 0.02 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXKWX | 307,888 | 16,607,478.89 | 0.1797 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXVIX | 307,888 | 16,607,478.89 | 0.1797 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXZMX | 451,000 | 517,183.13 | 0.0778 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXZMX | 504,000 | 585,327.19 | 0.088 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXGBX | 451,000 | 517,183.13 | 0.0778 |